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SPARC (secreted protein acidic and rich in cysteine) is a matricellular protein whose overexpression in 
malignant or tumor-stromal cells is often associated with increased aggressiveness and bad prognosis in a wide 
range of human cancer types, particularly melanoma. We established the impact that changes in the level of 
SPARC produced by malignant cells and neighboring stromal cells have on melanoma growth. Melanoma cell 
growth in monolayer was only slightly affected by changes in SPARC levels. However, melanoma growth in 
spheroids was strongly inhibited upon SPARC hyperexpression and conversely enhanced when SPARC 
expression was downregulated. Interestingly, SPARC overexpression in neighboring fibroblasts had no effect on 
spheroid growth irrespective of SPARC levels expressed by the melanoma cells, themselves. Downregulation of 
SPARC expression in melanoma cells induced their rejection in vivo through a mechanism mediated exclusively 
by host polymorphonuclear cells. On the other hand, SPARC hyperexpression enhanced vascular density, 
collagen deposition, and fibroblast recruitment in the surrounding stroma without affecting melanoma growth. 
In agreement with the in vitro data, overexpression of SPARC in co-injected fibroblasts did not affect melanoma 
growth in vivo. All the data indicate that melanoma growth is not subject to regulation by exogenous SPARC, 
nor by stromal organization, but only by SPARC levels produced by the malignant cells themselves.
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INTRODUCTION
Cancer progression is the result of a dynamic interaction 
between malignant cells, neighboring stromal cells such as 
fibroblasts and endothelial cells, and the host's immune cells 
that infiltrate the tumor mass. It is increasingly clear that 
proteins secreted by the tumor cells or surrounding stromal 
cells that become structural or transient components of the 
extracellular matrix (ECM) might play a significant role in 
cell-ECM interactions, helping the tumor cell to invade the 
neighboring stroma and disseminate (Murphy-Ullrich, 2001). 
One of the transient components of the ECM is the 
matricellular protein SPARC (secreted protein acidic and rich 
in cysteine). SPARC is a secreted glycoprotein associated with 
cell-matrix interactions during tissue remodeling, morpho­
genesis, migration, and proliferation (Bradshaw etal., 2001). 
SPARC is produced by different cell types, including 
endothelial cells, and was found to bind specific growth 
factors, such as vascular endothelial growth factor, platelet- 
derived growth factor, and basic fibroblast growth factor, or 
interact with their signaling pathways, suggesting that it might 
play a role in vasculogenesis (Yan and Sage, 1999). SPARC 
was also found to regulate matrix metalloproteinase expres­
sion and activity in normal and malignant cells, suggesting a 
role in enhanced tumor aggressiveness (Lane and Sage, 1994; 
Ledda etal., 1997b; Yan and Sage, 1999).
Several studies including expression array analysis indi­
cate that SPARC overexpression is associated with increased 
aggressiveness of various human cancers (Framson and Sage, 
2004, and references herein). In several adenocarcinomas, 
SPARC is faintly or not at all expressed in the malignant cells; 
however, its expression in stromal fibroblasts of human lung 
and colon carcinoma correlates with poor prognosis (Kou- 
kourakis eta/., 2003; Porte eta/., 1995). It has been proposed 
that SPARC's capacity to induce cell disengagement from the 
ECM favors cell migration and dissemination (Ledda et al., 
1997a; Rempel et al., 2001). Indeed, SPARC was found to 
enhance the migration and invasive capacity of melanoma 
2618 Journal of Investigative Dermatology (2007), Volume 127 <9 2007 The Society for Investigative Dermatology
F Prada et al.
Stroma-Derived SPARC and Melanoma Growth
and glioblastoma cells (Golembieski etal., 1999; Ledda etal., 
1997a; Rempel et al., 2001, 1998). In addition, SPARC 
increased the migration of prostate cancer cells toward bone 
extracts, highlighting its potential role as a chemotactic factor 
in bone metastasis (Thomas et al., 2000). More recently, 
SPARC was identified as one of the selected proteins that 
confer lung metastatic capacity to breast cancer cells (Minn 
et al., 2005). Moreover, SPARC was found to modulate the 
capacity of PMNs to eliminate melanoma cells in vitro 
(Alvarez et al., 2005).
Contrary to previous evidence, SPARC expression was 
associated with good prognosis in human neuroblastoma 
through the inhibition of angiogenesis (Yang et al., 2004). 
Moreover, SPARC-null mice exhibited enhanced peritoneal 
dissemination of ovarian cancer cells (Said and Motamed, 
2005). SPARC also inhibited the in vitro growth of some 
human pancreatic cancer cell lines (Sato et al., 2003; 
Puolakkainen et al., 2004). Furthermore, SPARC's effect on 
breast cancer growth also appears controversial because 
recent data demonstrated that its ectopic expression in 
MDA-MB231 cells inhibited cell capacity to metastasize to 
different organs, including bone and lungs (Koblinski et al., 
2005). In addition, reexpression of SPARC in colon cancer 
cells rendered the tumor more susceptible to proapoptotic 
chemotherapeutic molecules, suggesting that reduced levels of 
SPARC might promote apoptosis resistance (Tai et al., 2005).
This controversial evidence might indicate that SPARC's 
effect in cancer could be strongly dependent on the tumor 
cell type. Because SPARC is produced not only by the 
malignant cells but also by neighboring fibroblasts and 
endothelial cells, it is unclear whether the protein produced 
by the different cell components of a tumor mass might have 
different roles in tumor growth. In fact, recent attempts to 
elucidate the role of host-derived SPARC using SPARC-null 
mice led to opposite results; one group claimed enhanced 
tumor growth (Brekken et al., 2003), whereas others showed 
impaired tumor growth in SPARC-null mice (Sangaletti etal., 
2003). Despite this discrepancy both groups claimed that the 
major role of SPARC is associated with the assembly and 
function of the ECM.
In an attempt to understand the role of SPARC in 
melanoma, we modulated SPARC expression in malignant 
melanoma cells and in neighboring fibroblasts by over­
expressing or downregulating SPARC levels through adeno­
viral gene transfer. The effects of SPARC were assessed 
in vitro, using both melanoma cell monolayers and spheroids 
made of melanoma cells alone or combined with stromal 
cells, and in vivo following xenograft transplantation of 
melanoma cells alone or combined with stromal cells. We 
observed that the modulation of SPARC levels only in 
melanoma cells, and not in the neighboring stromal cells, 
affected melanoma cell growth.
RESULTS
Positive and negative modulation of SPARC levels does not 
profoundly affect melanoma cell growth in vitro
The human SPARC sense and antisense full-length cDNAs 
were cloned into an E1/E3-deleted recombinant adenoviral 
vector (Ad-SP and Ad-SPas, respectively) containing a Rous 
sarcoma virus (RSV) promoter driving gene transcription. 
Using 5 x 108 50% tissue culture infectious doses (TCID50)/ 
ml as the viral dose, 60-80% of melanoma cells, depending 
on the cell line, were transduced as assessed with Ad-/)gal 
(data not shown). Conditioned media obtained from A375N 
and IIB-Mel-J melanoma cells transduced with 5x108 
TCID50/ml Ad-SPas showed an important decrease in SPARC 
levels compared both to mock- and to Ad-/)gal-transduced 
melanoma cells (Figure 1a). Unexpectedly, transduction of 
melanoma cells with Ad-/)gal led to increased SPARC 
expression (Figure 1a). This increase was independent of 
the transgene because it was also observed with an 
adenoviral vector carrying CRE recombinase (data not 
shown). Time course analysis of SPARC expression showed 
that the maximal suppression of SPARC secretion was 
observed between days 4 and 5 (Figure 1b). Similarly, 
maximal SPARC secretion was observed at day 4 (Figure 
1b). At day 15, SPARC levels returned to basal levels (Figure 
1b). A day 4 loading control of total protein was also included 
(Figure 1c). Hyperexpression of SPARC in melanoma cells 
resulted only in a nonsignificant growth inhibitory effect in 
the two melanoma cell lines, whereas its downregulation had 
essentially no effect (Figure 1d and e).
Positive and negative modulation of SPARC levels inhibits and 
enhances, respectively, melanoma spheroid growth
To assess the role of SPARC produced by the different cell 
components of a tumor mass, we performed in vitro assays 
using spheroids made of melanoma cells alone or combined 
with fibroblasts. SPARC hyperexpression in A375N cells 
(A375N-SP) had a profound inhibitory effect on spheroid 
growth that was increasingly evident with time (Figure 2a). 
On the contrary, downregulation of SPARC expression in 
melanoma cells (A375N-SPas) induced a statistically sig­
nificant increase in spheroid growth capacity compared to 
Ad-/)gal-transduced cells (Figure 2a). Interestingly, cells 
transduced with Ad-/)gal (A375N-J?gal) also exhibited re­
duced growth capacity at the earliest time points, probably 
due to the increase in SPARC levels induced by Ad-/)gal 
transduction (Figure 2a). Western blot analysis shows that 
increased SPARC production by spheroids made of A375N-SP 
lasted for at least 10 days compared to the other groups 
(Figure 2b). On the other hand, spheroids made of A375N- 
SPas cells showed 20-25% reduced secretion of SPARC 
throughout the experiment, which is probably an under­
estimation of the reduction in SPARC secreted levels (Figure 
2b). A375N-/)gal and A375N-SPas spheroids showed a 
closely packed inner core surrounded by an outer layer of 
more loosely associated cell aggregate and neat borders 
(Figure 2c and d). On the contrary, A375N-SP spheroids were 
essentially devoid of the external layer, which was comple­
tely disassembled after 4 days of incubation (Figure 2e). Very 
similar results were obtained with IIB-Mel-J cells (data not 
shown). As a whole, these data indicate that SPARC 
hyperexpression in melanoma cells inhibits spheroid growth, 
whereas downregulation of SPARC expression showed the 
opposite effect, enhancing spheroid growth capacity.
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Figure 1. Modulation of SPARC levels in melanoma cells does not greatly impair their in vitro growth, (a) Western blot of conditioned media obtained from 
IIB-Mel-J and A37SN melanoma cells following transduction with the different adenoviral vectors. Samples were collected at day 4 after cell transduction, 
(b) Time course of SPARC secretion by IIB-Mel-J cells transduced with the various adenoviral vectors, (c) Loading control of total protein at day 4.
(d) In vitro growth of IIB-Mel-J cells transduced with the different adenoviral vectors, (e) In vitro growth of A37SN cells transduced with the different 
adenoviral vectors. Data are expressed as means + SD. An adenoviral TCIDsn/ml of S x 108 was used in b, c, d, and e.
SPARC overexpression by neighboring fibroblasts does not alter 
the growing rate of heterotypic melanoma spheroids
We next evaluated whether melanoma spheroid growth 
might be affected by the presence of neighboring fibroblasts. 
Heterotypic spheroids made of A375N-SPas and WI-38 cells 
showed an enhanced growth, although not statistically 
significant (P>0.05), whereas heterotypic spheroids made 
of A375N-SP and WI-38 cells were completely growth 
inhibited (Figure 3a).
Next, we assessed whether changes in the expression 
levels of SPARC in neighboring WI-38 cells might affect 
heterotypic spheroid growth. For this purpose, we transduced 
WI-38 cells, which express low levels of SPARC that are not 
detected in Western blots unless 10-fold concentrated 
medium is loaded (data not shown), with Ad-SP (WI38-SP). 
WI38-SP cells showed strong SPARC expression, similar to 
the levels produced by A375N-SP cells (Figure 3b). Figure 3 
shows that spheroid growth was not affected by SPARC levels 
secreted by neighboring fibroblasts, because no difference 
was found in heterotypic spheroid growth regardless of 
whether WI-38 cells overexpressed SPARC (Figure 3c). 
Because the endogenous levels of SPARC produced by 
melanoma cells could be sufficient to attain its maximal 
effect, we prepared spheroids made of WI38-SP mixed with 
A375N-SPas cells instead of native A375N melanoma cells. 
Even in this case, when SPARC levels produced by A375N- 
SPas cells were only 10-15% of the amount produced by 
native A375N cells, spheroid growth was not affected 
by the levels of SPARC produced by neighboring fibroblasts 
(Figure 3d). It can be concluded as a whole that heterotypic 
spheroid growth was affected only by the amount of SPARC 
secreted by the melanoma cells themselves, whereas SPARC 
produced by neighboring fibroblasts had no effect on 
spheroid growth.
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Figure 2. Modulation of SPARC levels in melanoma cells affects their growth as spheroids, (a) Growth rate of spheroids made of A37SN cells transduced 
with S x 108 TCID50/ml of the different vectors. Data are expressed as means + SD of at least seven spheroids and three different experiments (**P<0.01). 
(b) Conditioned media obtained from spheroids at the indicated time points were used to assess SPARC secretion. Loading control of total protein was included, 
(c-e) A37SN spheroid morphology at day 4. Bar = 1 SO/im.
Host polymorphonuclear cells are responsible for the rejection 
of human melanoma cells expressing reduced SPARC levels 
The next experiments aimed to establish whether changes in 
SPARC levels produced by melanoma cells or by neighboring 
stromal cells might affect the in vivo growth capacity of 
melanoma cells. Confirming previous studies (Alvarez et al., 
2005), the in vivo growth capacity of melanoma cells 
expressing reduced SPARC levels (Mel J-SPas) was strongly 
inhibited in nude mice compared to control Mel J-/?gal or 
mock-transduced melanoma cells (Figure 4a). Interestingly, 
more than 50% of mice injected with Mel J-SPas survived 
after 100 days, compared to none in the other two groups 
(Figure 4b). Similar effects were observed with A375N cells 
(Alvarez et al., 2005, and data not shown). Confirming 
previous results (Alvarez et al., 2005), tumor growth 
inhibition was accompanied by a fourfold increase in the 
amount of intratumoral recruited polymorphonuclear cells 
(PMN; data not shown). Because previous studies suggested 
that host PMN might be responsible for the rejection of 
malignant cells, we depleted PMN by using specific 
neutralizing antibodies. Initial experiments showed that 
anti-Gr-1 antibody administration (RB6-8C5 clone) depleted 
host PMN for at least 15 days (data not shown). Administra­
tion of anti-PMN antibodies completely reverted the inhibi­
tion of melanoma growth induced by downregulation of 
SPARC expression, indicating that host PMN were respon­
sible for melanoma rejection (Figure 4c). Interestingly, 
depletion of host PMN also accelerated the in vivo growth 
of non-genetically modified IIB-Mel-J cells, highlighting a 
general role of host PMN in controlling human melanoma 
xenograft growth (Figure 4c).
SPARC hyperexpression by melanoma cells promotes stroma 
reorganization without affecting their in vivo tumor growth 
Our previous data demonstrated that melanoma spheroid 
growth was greatly inhibited following SPARC overexpres­
sion. To establish whether SPARC hyperexpression might also 
affect the in vivo growth of melanoma cells, we xenotrans- 
planted nude mice with melanoma cells transduced ex vivo 
with Ad-SP. In contrast to the results obtained with spheroids, 
SPARC hyperexpression in A375N cells did not alter their 
in vivo growth at all compared to control cells transduced 
ex vivo with Ad-/)gal (Figure 4d). Similar results were 
obtained with 11 B-Mel-J cells (Figure 4e).
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Figure 3. Modulation of SPARC levels in neighboring fibroblasts has no 
effect on heterotypic spheroid growth, (a) Growth rate of spheroids made of 
wild-type WI-38 fibroblasts mixed with A375N cells transduced with the 
various adenoviral vectors, (b) Western blot of the conditioned media of 
WI-38 cells transduced with the various vectors. A375N-/>gal and A375N-SP 
conditioned media were included as a comparison. Loading control of total 
protein was also included, (c) Growth rate of spheroids made of A375N cells 
mixed with WI-38 fibroblasts transduced with the various adenoviral vectors, 
(d) Growth rate of spheroids made of A375N-SPas cells mixed with WI-38 
fibroblasts transduced with the various adenoviral vectors. Data are expressed 
as means + SD of at least seven spheroids and three different experiments 
(**p<0.001). An adenoviral TCID50/ml of 5 x 108 was used.
Interestingly, however, clear differences were observed when 
immunohistological studies were performed. Mel J-SP tumors 
hyperexpressed SPARC in vivo for at least the first 5 days 
compared to control cells transduced with Ad-/?gal (Figure 5a 
and b). SPARC hyperexpression by melanoma cells was also 
accompanied by an increased amount of fibroblasts that were 
mainly located in a collagen-rich tumor area (Figure 5c). 
Indeed, Masson's trichrome staining revealed a twofold 
increase in collagen deposition in melanoma tumors over­
expressing SPARC compared to control tumors (Figure 5f). 
This collagen was observed at the tumor interface between 
the malignant nests and the surrounding host tissue (compare 
Figure 5d and e). On the other hand, we observed no 
differences in the amount of the recruited inflammatory 
infiltrate following SPARC hyperexpression (data not shown). 
Immunohistochemical analysis using an anti-CD31 antibody 
revealed increased angiogenesis, as peritumoral microvessel 
density was significantly augmented in melanoma tumors 
hyperexpressing SPARC compared to the control (Figure 5g 
and h). This difference was clearly evidenced at day 5 after 
cell administration (Figure 5i). Interestingly, autopsies of the 
mice at 40 days revealed no differences, neither in the 
amount of vessels nor in fibroblast recruitment or collagen 
deposition, between melanomas obtained from cells that 
hyperexpressed SPARC and control melanomas (data not 
shown). Finally, no difference in the in vivo proliferation rate 
was observed as assessed with an anti-Ki-67 antibody (data 
not shown). Thus, all the evidence indicates that the 
remarkable changes in stroma composition observed in 
tumors transiently hyperexpressing SPARC did not affect 
melanoma growth.
Coadministration of fibroblasts overexpressing SPARC or not 
has no effect on melanoma outcome
In the previous studies it could be argued that human 
melanoma cells could have been unable to establish proper 
interactions with murine stroma. Therefore, we co-injected 
melanoma cells with human fibroblasts and followed their in 
vivo growth capacity in nude mice. We initially transduced 
IIB-Mel-J cells ex vivo with Ad-SP and co-injected them into 
nude mice with an equivalent amount of WI-38 cells. 
Coadministration of WI-38 cells had no effect on the in vivo 
growth capacity of Mel J-SP cells compared to control Mel J- 
Agal cells coadministered with WI-38 cells (Figure 6a). In 
concordance with the spheroid data, overexpression of 
SPARC in coadministered WI-38 cells also had no effect on 
the in vivo growth of unmodified IIB-Mel-J cells (Figure 6b). 
To establish whether coadministration of transformed fibro­
blasts might have a different effect, we co-injected IIB-Mel-J 
cells with WI-38 VA fibroblasts, a transformed variant stably 
expressing the SV40 large T antigen, which were transduced 
ex vivo with Ad-SP. Figure 6 shows no effect of SPARC 
overexpression in coadministered WI-38 VA fibroblasts on 
melanoma growth outcome (Figure 6c). This set of experi­
ments indicates as a whole that SPARC overexpression in 
fibroblasts had no effect on melanoma growth.
DISCUSSION
Here, we show that the in vitro and in vivo growth capacity of 
human melanoma cells depends essentially on SPARC levels 
produced by the malignant cells themselves, whereas SPARC 
produced by stromal cells has no apparent role on melanoma 
growth. Indeed, manipulation of SPARC levels in neighboring 
human fibroblasts in heterotypic spheroids or in vivo did not 
affect melanoma cell growth. Moreover, changes in stroma 
organization induced by SPARC did not substantially affect 
melanoma growth.
Despite the contradictory results on tumor growth that we 
have extensively presented in the introduction, it was 
proposed that the main role of host-derived SPARC in cancer 
progression is in the appropriate organization of the ECM
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Figure 4. Downregulation but not upregulation of SPARC expression affects the in vivo melanoma growth capacity, (a) IIB-Mel-J cells transduced with 
the different vectors were xenotransplanted in nude mice as described, (b) Kaplan-Meier curve showing mouse survival, (c) 11 B-Mel-J cells transduced or not 
with Ad-SPas and injected into nude mice in the presence of anti-PMN or anti-CD4 antibodies (RB6-8C5 and GK1.5 hybridoma clones, respectively).
(d) In vivo growth of A375N cells transduced with Ad-SP. (e) In vivo growth of 11 B-Mel-J cells transduced with Ad-SP. Tumor volume was expressed as the 
mean + SE of at least five mice and at least two independent experiments (*P<0.05 and **P<0.01). An adenoviral TCID50/ml of 5 x 108 was used.
Figure 5. Increased collagen deposition, angiogenesis, and fibroblast recruitment in melanoma tumors hyperexpressing SPARC do not affect tumor 
growth. Immunohistochemical expression of SPARC in (a) control Mel J-/Jgal and (b) Mel J-SP cells. The square represents the area of magnification shown in 
the inset. The arrows show malignant cells (b) hyperexpressing or (a) not hyperexpressing SPARC, (c) Quantification of recruited fibroblasts, (d and e) Trichromic 
Masson staining in (d) control Mel J-/Jgal and (e) Mel J-SP tumors, (f) Quantification of collagen surrounding the tumor area, (g and h) Immunohistochemical 
staining of CD31-positive vessels in (g) control Mel J-/Jgal and (h) Mel J-SP tumors. The arrows in the insets show microvessel areas, (i) Quantification of 
microvessels. Data in c, f, and i are expressed as means + SD (*P<0.05 and **P<0.01). Bar = 200 ¿zm; inset bar = 50/zm. Data were obtained from samples 
collected 5 days after injection.
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Figure 6. Coadministration of fibroblasts overexpressing SPARC or not has no effect on melanoma cell growth, (a) WI-38 fibroblasts mixed either with
Mel J-/?gal or with Mel J-SP were co-injected into nude mice, (b) 11 B-Mel-J cells mixed either with WI38-/?gal or with WI38-SP cells were co-injected into nude 
mice, (c) 11 B-Mel-J cells mixed either with WI38 VA-/?gal or with WI38 VA-SP cells were co-injected into nude mice. Tumor volume was expressed as the 
mean + SE of at least five mice and at least two independent experiments. An adenoviral TCID50/ml of 5 x 108 was used.
(Brekken et al., 2003). It was proposed that the stroma may 
act as a shield to protect tumors from the immune infiltrate; 
thus, a less-dense stroma such as the one observed in SPARC- 
null mice may allow recruitment of immune infiltrate and 
hence tumor rejection (Sangaletti etal., 2003). Alternatively, 
the less-dense stroma in SPARC-null mice also showed a 
reduced blood vessel number, suggesting that a smaller blood 
supply might have also affected tumor growth (Sangaletti 
et al., 2003). The discrepancy regarding tumor growth was 
suggested to be based on the different interactions that tumor 
cells establish with the surrounding stroma; certain tumor 
cells might favor proteolysis of stromal proteins leading to 
angiogenesis inhibition, whereas other cell types might 
induce the opposite, thus inhibiting or promoting tumor 
growth (Sangaletti etal., 2003; Chlenski etal., 2006).
On the basis of previous discrepancy, we attempted to 
establish the ECM role in melanoma growth by initially 
modulating SPARC levels in melanoma cells and monitoring 
tumor growth and ECM organization. We conclude that the 
increases in angiogenesis, collagen deposition, and fibroblast 
recruitment induced by SPARC hyperexpression in melano­
ma cells have no significant effect on melanoma outcome, 
clearly indicating that melanoma growth is essentially not 
affected by the composition or organization of the neighbor­
ing stroma. It is of note that stromal reorganization was 
observed at the initial stages of melanoma growth, when 
transient adenoviral-directed hyperexpression of SPARC was 
higher. In fact, necropsy of the mice at 40 days revealed no 
differences in ECM organization between control and SPARC- 
hyperexpressing melanomas. Whether sustained SPARC 
overexpression in melanoma cells and concomitant remodel­
ing of ECM might result in increased melanoma growth 
in vivo remains to be tested. However, in initial studies, 
we observed that stable hyperexpression of SPARC in 
melanoma cells resulted in a nonsignificant inhibition of in 
vivo tumor growth, supporting the data obtained in the 
present studies (Viale et al., manuscript in preparation). 
Moreover, the fact that tumor cell rejection occurs during the 
first 72 hours suggests that 10 days of SPARC hyperexpression 
must suffice for the protein to exert an effect on tumor 
growth. Because human melanoma cells might also be 
disadvantageous in the generation of proper interactions with 
rodent stromal cells, we modulated SPARC levels in 
coadministered human fibroblasts. We conclude that the 
presence or absence of neighbor human fibroblasts expres­
sing or not expressing SPARC has no effect on melanoma 
growth, strengthening the fact that the changes in surround­
ing stroma induced by SPARC have no profound influence on 
melanoma outcome. The question as to whether the amount 
and biochemical characteristics of SPARC produced by 
neighboring fibroblasts might define its potential paracrine 
effect is currently under investigation.
It was of note that SPARC overexpression almost 
obliterated melanoma cell growth as spheroids, whereas 
SPARC downregulation increased spheroid growth. Because 
SPARC hyperexpression had little or no effect at all when 
cells were grown in vitro as monolayers or in vivo, it is 
tempting to speculate that SPARC might have affected the 
anchorage-independent growth capacity of melanoma cells. 
In addition, we observed a reduced clonogenic capacity of 
melanoma cells grown in semisolid agar following over­
expression of SPARC (data not shown). No previous evidence 
was presented for the potential role of SPARC on anchorage­
independent growth of tumor cells. Recent studies using cells 
obtained from SPARC-null mice indicated that SPARC might 
regulate the cell cycle through the concurrently induced 
expression of p107 and cyclin A (Basu et al., 1999). Cyclin A 
has been shown to be a direct target of c-Jun and to be 
necessary for c-Jun-induced anchorage-independent growth 
of certain cancer cells (Katabami et al., 2005). Interestingly, 
SPARC expression has been shown to be both upregulated 
and downregulated in response to c-Jun overexpression 
(Kraemer et al., 1999; Vial et al., 2000; Briggs et al., 
2002;). Overall these data suggest a potential link between 
SPARC, cyclin A, Jun, and anchorage-independent growth of 
tumor cells. It might be hypothesized that the timely 
regulation of SPARC levels might allow melanoma cells to 
grow in an anchorage-independent way favoring metastatic 
dissemination.
The role of SPARC in angiogenesis is a matter of 
controversy. Several studies have shown that SPARC might 
impair angiogenesis through the inhibition of the vascular 
endothelial growth factor mitogenic effect on endothelial 
cells, which in some cases inhibited tumor growth (Kupprion 
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etal., 1998; Said and Motamed, 2005; Chlenski etal., 2006; 
Nozaki et al., 2006), whereas others have shown that 
vascular endothelial growth factor might upregulate SPARC 
levels produced by endothelial cells (Kato etal., 2001) and 
that SPARC by itself might promote angiogenesis (Brekken 
et al., 2003). This data indicate that SPARC hyperexpression 
promotes angiogenesis in melanoma tumors as assessed by 
the increased number of microvessels stained with an anti- 
CD31 antibody. Recent studies demonstrated that SPARC 
cleavage by MMPs released fragments that stimulated or 
inhibited proliferation and migration of endothelial cells in 
mutually exclusive manners (Sage et al., 2003). Moreover, 
SPARC has been shown to modulate MMP expression in 
melanoma cells (Ledda et al., 1997a). Thus, the evidence 
indicates that the role of SPARC in angiogenesis is dependent 
on the tumor cell type and the availability of concurrent 
factors such as MMPs that might also influence the same 
process.
Here we show that depletion of host PMN by specific 
antibodies is sufficient to completely revert melanoma 
rejection, thereby providing definitive evidence on the 
central role of host PMN in this process. The role of host 
PMN in tumor promotion or rejection is still under discus­
sion. Various studies have shown that PMN are responsible 
for rejection of tumor cells ectopically expressing cytokines 
such as G-CSF, IL-2, or Fas L (Alvarez etal., 2005; Motomu 
Shimizu etal., 2005; Stoppacciaro etal., 1994). On the other 
hand, others have also shown that PMN were required for 
acquisition of a metastatic phenotype of benign murine 
fibrosarcoma cells (Tazawa et al., 2003). Also, PMN 
depletion in nude mice by using the RB6-8C5 antibody 
inhibited growth of tumors induced by UV light (Pekarek 
et al., 1995). It appears plausible, then, that PMN might play 
a different role in different tumor types or they might behave 
differently at different stages of tumor growth.
In conclusion, these studies show that SPARC levels 
produced only by the melanoma cells themselves affect 
tumor growth, whereas these malignant cells are essentially 
resistant to external SPARC influence as assessed both in vitro 
and in vivo. Although the precise role of the stroma in 
melanoma growth is still elusive, we speculate that it might 
become crucial only at certain stages of melanoma develop­
ment.
MATERIALS AND METHODS
Cells and cell cultures
A375N human melanoma cells were grown in melanoma medium 
(DMEM/F12, 3.6g/l HEPES, 1.5 g/l NaHCO3, 5 mg/l insulin, 17.6mg/l 
ascorbic acid, and 0.3 g/l galactose). IIB-Mel-J melanoma cells were 
grown in melanoma medium supplemented with 5 ^g/l epidermal 
growth factor, 500/ig/l transferrin, and 0.92g/l NaHCO3. Human 
embryonic fibroblasts (WI-38 and WI-38 VA-13) were grown in 
DMEM supplemented with MEM nonessential amino acids. All 
complete media were supplemented with 10% v/v fetal bovine 
serum and antibiotics. Cell cultures were maintained at 37°C in a 5% 
CO2 humidified incubator. Cell culture reagents were from Gibco 
(Invitrogen, Grand Island, NY).
Construction of adenoviral vectors and cell transduction
The adenoviral vectors carrying human SPARC sense (Ad-SP) and 
antisense (Ad-SPas) were prepared using the full-length human 
SPARC cDNA (Podhajcer et al., 1996). A 1.7 kb Sall fragment 
containing the cDNA was released from pBluescript SK+ and 
cloned into the Sall site of the shuttle vector pADPSY-LTRSVpolyA. 
To obtain the recombinant adenoviruses, each of the shuttle vectors 
containing the SPARC cDNA in both orientations was cotransfected 
into human embryonic kidney 293 cells with the large C/al fragment 
(2.6-100mu) of Ad5 DNA lacking the E3 regions (Lieber et al., 
1996). Viral stock titers were determined by optic density and 
TCID30 (Reed, 1938). An additional adenoviral vector, containing 
527bp of Escherichia coli /?-galactosidase coding sequence, was 
prepared following the same protocol (Ad-/?gal). All viral stocks 
contained <12.5 endotoxin units/ml as assessed using the E-Toxate 
kit (Sigma Co., St Louis, MO).
For cell transduction, cells were grown up to 80% confluence in 
monolayer and transduced with 5 x 108 TCID30/ml of the different 
adenoviral vectors for 6 hours. At the end, the transduction medium 
was replaced with fresh complete medium; cells were incubated for 
an additional 20 hours, trypsinized, counted, and used. Transduction 
efficiency was assessed 36 hours after transduction with Ad-/?gal 
followed by X-gal (Alam and Cook, 1990). Experiments were run 
only when transduction efficiency was better than 60 and 75% for 
IIB-Mel-J and A375N cells, respectively.
Production of monoclonal antibodies and Western blot analysis 
Monoclonal antibodies recognizing human SPARC were obtained by 
intrasplenic immunization of BALB/c mice with 200 fig of human 
rSPARC in 50 fil of phosphate-buffered saline (PBS) (Wayne et al., 
2006). Positive clones were mostly of the IgM/r and lgM2 isotypes 
(IsoStrip; Roche Molecular Biochemicals, Indianapolis, IN). Anti- 
SPARC (IgM/r) 7A5 monoclonal antibody was purified from an 
ascitic fluid by using Sephacryl S-400 (GE Healthcare, Uppsala, 
Sweden). To obtain conditioned media, nearly confluent cells were 
washed twice with PBS and kept in serum-free medium. After 
24hours, the medium was collected, supplemented with 1 itim 
phenylmethylsulfonyl fluoride, and quantified using a NanoOrange 
Protein Quantitation Kit (Molecular Probes, Eugene, OR). One 
microgram of protein was separated in SDS-PAGE under reducing 
conditions and transferred onto nitrocellulose membranes (Schlei­
cher & Schuell Bioscience, London, UK). Loading controls were 
performed to validate protein quantification using Sypro Ruby 
protein gel stain (Sigma). After being blocked with skimmed milk 
in PBS, membranes were incubated with mAb-7A5 overnight at 4°C. 
After being washed with 0.05% Tween-20 in PBS, membranes were 
further incubated for 2 hours at room temperature with horseradish 
peroxidase-conjugated goat anti-mouse antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA). Bands were detected using the 
ECL Plus Western Blotting Detection System (GE Healthcare, 
Buckinghamshire, UK). SPARC levels were quantified by densit­
ometer analysis using the ImageJ 1.33u software (National Institutes 
of Health, Bethesda, MD).
Proliferation assays
Cell proliferation was measured using the colorimetric MTT assay 
(Sigma). Briefly, 3 x 103 cells/well were seeded onto a 96-well plate 
in a final volume of 100 fil per well. At each time point, 10 fil of 
www.jidonline.org 2625
F Prada et al.
Stroma-Derived SPARC and Melanoma Growth
5 mg/ml 3-(4,5-dimethylthiazol-3-yl)-2,5-diphenyl tétrazolium bro­
mide was added to each cell culture plate. Two hours later, the 
formazan dye was solubilized and read at 550 nm optical density as 
described (Denizot and Lang, 1986).
Three-dimensional spheroids
Ninety-six-well tissue culture plates were coated with 75 fi\ of 1% 
agarose in PBS. Nearly confluent cells were washed twice with PBS, 
trypsinized, and seeded at 104cells/well in 150^1 of melanoma 
medium for melanoma cells and DMEM for fibroblasts to obtain a 
single homotypic spheroid per well. Heterotypic spheroids were 
built using 5 x 103 each of A375N and WI-38 cells grown in a mix of 
melanoma medium and DMEM. Seventy-five microliters of super­
natant was carefully removed from each well every 3 days and 
replaced with fresh medium. Spheroid size was measured every 2 
days using an inverted microscope containing a x 10 eyepiece ruler 
graduated to 0.01 mm. Spheroid volume was determined using the 
equation V= (LW1) x 0.5, where L is length and W is width of the 
spheroid. Spheroid conditioned media were obtained by pooling five 
spheroids followed by three washes with PBS and incubation in the 
absence of serum for 24 hours.
In vivo tumor growth
For assessment of the in vivo tumor growth, A375N and IIB-Mel-J 
human melanoma and WI-38 fibroblast cell lines were transduced 
ex vivo with Ad-SP, Ad-SPas, and Ad-/fgal. Twenty hours later cells 
were trypsinized, counted, and resuspended in 100^1 of PBS. Six-to 
8-week-old male athymie N:NIH(S>-nu mice were subcutaneously 
injected into the left flank with 5 x 106 IIB-Mel-J or 3 x 106 A375N 
melanoma cells or a mix of 5 x 106 IIB-Mel-J and 4 x 106 fibroblasts. 
Perpendicular diameters were used to determine tumor volume, as 
V=dj x d\/2, where ds is the smaller diameter and dj is the larger 
one. All in vivo experiments followed institutional guidelines 
approved by NIH authorities.
Depletion of PMCs
Conditioned medium containing anti-Gr-1 antibody was prepared 
from RB6-8C5 hybridoma clone (Dr. Coffman, DNAX Research 
Institute, Palo Alto, CA), whereas the anti-CD4 antibody was 
prepared from a GK1.5 hybridoma clone (TIB 207™, ATCC, 
Manassas, VA). For PMN depletion, mice were intraperitoneally 
injected every 2 days starting 2 days before tumor inoculation with 
the specific RB6-8C5 antibody. To quantify the effect of RB6-8C5 on 
PMN depletion, we induced PMN mobilization by injecting casein 
and then recovered PMN from the abdominal cavity (Luo and 
Martin, 2006). Briefly, animals were injected twice (18 and 3 hours 
before they were killed) intraperitoneally with 1 ml of 4% casein in 
PBS. The cellular suspension obtained from the peritoneal exudates 
was centrifuged 10 minutes at 1000 r.p.m. and the relative amount of 
PMN was assessed by differential counting using May Grunwald- 
Giemsa staining of the smear.
Histology and immunohistochemistry
Eight-micrometer-thick tumor sections were deparaffinized in xylene 
and rehydrated in graded ethanol. For antigen unmasking, sections 
were immersed in citrate buffer (pH = 6) and boiled twice in a 
microwave oven. Endogenous peroxidase activity was blocked by 
soaking the sections in 3% hydrogen peroxide in methanol for 
15 minutes. Nonspecific binding sites were blocked by incubating 
the sections in normal goat serum (10% in PBS). Excess serum was 
then removed and the tissue sections were incubated overnight with 
anti-hSPARC rabbit polyclonal antibody (Ledda et al., 1997b) at 
1/200 dilution. After the slides were washed twice in PBS for 
10 minutes, the sections were incubated with biotinylated goat anti­
rabbit antibody (Vector Laboratories, Burlingame, CA) at 1/400 
dilution for 45 minutes, followed by a PBS wash. The sections were 
subsequently incubated with Vectastain ABC reagent (Vector 
Laboratories, Burlingame, CA) for 45 minutes. Color was developed 
by incubating the sections with liquid diaminobenzidine (substrate 
chromogen system, DakoCytomation, Carpinteria, CA). Finally, the 
sections were counterstained with hematoxylin, dehydrated, and 
mounted.
For total collagen detection, deparaffinized sections were stained 
with Masson's trichrome according to standard protocols. Collagen 
content was quantitatively determined using the Image-Pro Plus 
software (Media Cybernetics, Silver Springs, MD). Briefly, five areas 
from serial sections of tumor explants obtained from at least four 
different animals were digitally selected. The collagen-rich area of 
each selected field was measured using the “area measurement" 
within the "count tool" belonging to the Image-Pro Plus software. 
Fibroblasts were counted by our pathologist (AIB) under a light 
microscope.
For CD31 detection, tumors were fixed in 4% paraformaldehyde 
for 1 hour, cryopreserved overnight in 30% sucrose, embedded in 
tissue OCT, and stored at —20°C. Cryostat sections of 9 fim were 
mounted on gelatin-coated slides and rehydrated in graded ethanol. 
For antigen retrieval, a 3 minute pepsin digest was performed. Slides 
were incubated overnight with anti-CD31 (PharMingen, San Diego, 
CA) at a 1/600 dilution. After being washed, the sections were 
incubated with 1/400 dilution of biotinylated goat anti-rat antibody 
Oackson ImmunoResearch Laboratories, West Grove, PA). Product 
visualization was performed as described above. Slides were 
counterstained with hematoxylin. PBS was used instead of the first 
antibody as a control. After the immunostaining, the entire tumor 
section was scanned at low power (x 40) to identify areas of 
neovascularization. Individual or small-caliber microvessels were 
then counted under high power ( x 400) to obtain a vessel count in a 
defined area. Data were obtained from three animals at each time 
point. We analyzed five areas of each sample.
Statistical analysis
Survival rates were calculated with the Kaplan-Meier method and 
their differences were evaluated by the log-rank test. Statistical 
difference between groups was determined by one-way analysis of 
variance follow by a Dunnett's multiple comparison test. A P-value 
of <0.05 was considered statistically significant. Data analysis was 
performed with the Prism GraphPad (GraphPad Software, Inc., 
San Diego, CA).
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